Switch theme
Sign up to access all valuation multiples
Celltrion Inc is a Korea-based company principally engaged in the research, development, and manufacture of therapeutic proteins. The company mainly manufactures biosimilar products, which are used to treat breast cancer, rheumatoid arthritis disease, Crohn's disease, Hodgkin's lymphoma, colorectal cancer, rheumatoid arthritis, respiratory syncytial virus, colon cancer, and others.
1991
n/a
LTM Revenue $2.6B
LTM EBITDA $813M
$25.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Celltrion has a last 12-month revenue of $2.6B and a last 12-month EBITDA of $813M.
In the most recent fiscal year, Celltrion achieved revenue of $2.4B and an EBITDA of $729M.
Celltrion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Celltrion valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.5B | $2.4B | XXX | XXX | XXX |
| Gross Profit | $704M | $717M | XXX | XXX | XXX |
| Gross Margin | 47% | 30% | XXX | XXX | XXX |
| EBITDA | $631M | $729M | XXX | XXX | XXX |
| EBITDA Margin | 43% | 30% | XXX | XXX | XXX |
| Net Profit | $366M | $365M | XXX | XXX | XXX |
| Net Margin | 25% | 15% | XXX | XXX | XXX |
| Net Debt | $160M | $892M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Celltrion's stock price is KRW 163500 (or $111).
Celltrion has current market cap of KRW 35.59T (or $24.3B), and EV of KRW 36.64T (or $25.0B).
See Celltrion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25.0B | $24.3B | XXX | XXX | XXX | XXX | $1.90 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Celltrion has market cap of $24.3B and EV of $25.0B.
Celltrion's trades at 9.6x LTM EV/Revenue multiple, and 30.7x LTM EBITDA.
Analysts estimate Celltrion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Celltrion and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $25.0B | XXX | XXX | XXX |
| EV/Revenue | 10.3x | XXX | XXX | XXX |
| EV/EBITDA | 34.2x | XXX | XXX | XXX |
| P/E | 84.2x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | 64.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCelltrion's NTM/LTM revenue growth is 25%
Celltrion's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Celltrion's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Celltrion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Celltrion and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 63% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 55% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 33% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Celltrion acquired XXX companies to date.
Last acquisition by Celltrion was XXXXXXXX, XXXXX XXXXX XXXXXX . Celltrion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Celltrion founded? | Celltrion was founded in 1991. |
| Where is Celltrion headquartered? | Celltrion is headquartered in South Korea. |
| Who is the CEO of Celltrion? | Celltrion's CEO is Mr. Woo-Sung Ki. |
| Is Celltrion publicy listed? | Yes, Celltrion is a public company listed on KRX. |
| What is the stock symbol of Celltrion? | Celltrion trades under 068270 ticker. |
| When did Celltrion go public? | Celltrion went public in 2005. |
| Who are competitors of Celltrion? | Similar companies to Celltrion include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Celltrion? | Celltrion's current market cap is $24.3B |
| What is the current revenue of Celltrion? | Celltrion's last 12-month revenue is $2.6B. |
| What is the current EBITDA of Celltrion? | Celltrion's last 12-month EBITDA is $813M. |
| What is the current EV/Revenue multiple of Celltrion? | Current revenue multiple of Celltrion is 9.6x. |
| What is the current EV/EBITDA multiple of Celltrion? | Current EBITDA multiple of Celltrion is 30.7x. |
| What is the current revenue growth of Celltrion? | Celltrion revenue growth between 2023 and 2024 was 63%. |
| Is Celltrion profitable? | Yes, Celltrion is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
